tbuckley/cabot-search huggingface dataset:
Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.
Authors: Matthias Stelljes, Martin Bornhaeuser, Matthias Kroger, Joerg Beyer, Maria C. Sauerland, Achim Heinecke, Bjorna Berning, Christian Scheffold, Gerda Silling, Thomas Buchner, Andreas Neubauer, Axel Arthur Fauser, Gerhard Ehninger, Wolfgang E. Berdel, Joachim Kienast
Journal: Blood (2006)
Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.
Authors: Susan D. Demo, Monette A. Aujay, Eileen Goldstein, Guy J. Laidig, Francesco Parlati, Yan Lu, Kevin D. Shenk, Congcong M. Sun, Catherine Sylvain, Tina M. Woo, Hanjie Zhou, Mark K. Bennett
Journal: Blood (2006)
The complex formation between pirin and IkappaBalpha supports the prolonged NFκB activation in tumor cells
Authors: Nickolay Neznanov, Anna Kondratova, Lubov Neznanova, Andrei V. Gudkov
Journal: Cancer Research (2005)

787  The constant activation of NFkB makes tumor cells resistant to pro-apoptotic stimulus and hypoxia. The activation of NFkB stimulates the transcription from the IkB alpha (IkBa) gene, and this regulatory loop decreases the NFkB activity after stimulation in the normal cells. This mechanism leads to the fast down regulation of NFkB activity after stimulation by TNF and IL1, and prevents the persistent activation of NFkB, even when the NFkB-activating factors are present in the media. The additional mechanisms should be present in the cells to keep NFkB constantly activated. Many tumor cells have an increased level of NFkB activity without additional stimulation. In our previous experiments, we isolated the protein pirin as a cellular interactor with poliovirus protein 3A. Pirin was described as a protein, which can be found in the complex with transcription factor NF1 and with an ankyrin repeat-containing protein bcl3 from IkB family (Dechend R. et al. 1999). The other member of IkB family is IkBa, an ankyrin repeat-containing cytoplasmic chaperon and a major suppressor of NFkB. We found that IkBa and pirin form a complex in vivo, and are co-localized in the cells. The level of pirin is elevated in tumor cells like HeLa, 293T, and melanomas in comparison with primary fibroblasts, primary epithelial cells, and benign cells from the moles. There is a good correlation between the level of pirin expression and the level of NFkB activity in the cells. The over-expression of pirin in fibroblasts increased NFkB-specific transcription. The depletion of pirin by siRNA-specific mechanism decreases NFkB activity and activates apoptosis in HeLa cells. We hypothesize that pirin may have a function as an IkB -binding protein that supports NFkB activity in tumor cells.
Circulating fibronectin contributes to mesangial expansion in a murine model of type 1 diabetes
Authors: Verena Klemis, Hiba Ghura, Giuseppina Federico, Carina Würfel, Anke Bentmann, Norbert Gretz, Tatsuhiko Miyazaki, Hermann-Joseph Gröne, Inaam A. Nakchbandi
Journal: Kidney International (2017)
The El Greco fallacy and pupillometry: Pupillary evidence for top-down effects on perception
Authors: Weizhen Xie, Weiwei Zhang
Journal: Behavioral and Brain Sciences (2016)

Abstract In this commentary, we address the El Greco fallacy by reviewing some recent pupillary evidence supporting top-down modulation of perception. Furthermore, we give justification for including perceptual effects of attention in tests of cognitive penetrability. Together, these exhibits suggest that cognition can affect perception (i.e., they support cognitive penetrability).
QOL-06IMPORTANCE OF TASK SELECTION FOR ACTIVATION OF WERNICKE'S AREA: A FUNCTIONAL MRI STUDY COMPARING 3 DIFFERENT WIDELY USED TASKS
Authors: Islam Hassan, Pascal O. Zinn, Scott Faro, Feroze Mohamed, Jeffery S. Weinberg, Raymond Sawaya, Rivka Colen
Journal: Neuro-Oncology (2015)

INTRODUCTION: Multiple tasks are available, which can be used for activation of Broca's area. However, localization of Wernicke's area remains a challenge. Task selection is very essential for proper identification of Wernicke's area prior to surgical resection or intervention. Here, we compare the results of three different activation tasks, sentence completion (SC), word generation (WG) and category naming (CAT) for localization of Wernicke's area. METHODS: 11 right handed healthy volunteers (22 to 55y) were included. IRB approval was obtained. Subjects were trained on each task prior to scanning. GE Healthcare provided equipment. Scans were done on a GE 3.0T, 32 channel head coil. Experiments were block design. For SC, subjects were presented with incomplete sentences to complete. On WG and CAT, subjects were asked to generate words that either start with the alphabet shown on the screen or related to the category displayed. During rest, subjects were presented with a gibberish sentence during the first task and a picture of a hand on the second and third tasks. FMRI was acquired using EPI sequences. RESULTS: Multiple uncorrected P values of cluster probability were used, ranging from 0.05 to 0.001. ROI analysis of Wernicke's spatial co ordinate revealed no activation in CAT and WG across different P values. However, for Sentence Completion task with a cluster probability of an uncorrected P value (<0.001), activation in Wernicke's area was detected with a T value of 4.45. On individual analysis, during SC 9 out of 11 (82%) subjects shows activity in wernicke's spatial co ordinates, compared to only 2 (18%) and 3 (27%) subjects with activity in the same co ordinates in WG and CAT, respectively. CONCLUSIONS: Sentence completion task is a more effective task in localizing Wernicke's areas compared to Word generation and Category naming tasks.
Brucellosis (Undulant Fever): Clinical and Subclinical
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evidence of Different Subspecies of Microparticles (MP) Derived from Red Blood Cells (RMP) and Comparison of Their Phenotypes and Procoagulant Activity.
Authors: Wenche Jy, Jaehoon Bang, Loreta Bidot, Andrew Lin, Joaquin J. Jimenez, Vincenzo Fontana, Eugene Ahn, Yeon-Soong Ahn
Journal: Blood (2006)
Umbilical Cord Blood Transplant after Reduced Intensity Conditioning Provides Outcomes Comparable HLA-Matched Siblings for Patients with High Risk and Advanced Acute Myeloid Leukemia.
Authors: Claudio G. Brunstein, Daniela Setubal, Marcie Tomblyn, Todd DeFor, Mukta Arora, Linda J. Burns, Jeffrey S. Miller, Daniel J. Weisdorf, John E. Wagner
Journal: Blood (2006)
CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.
Authors: Matteo Renzulli, C. Terragna, N. Testoni, E. Montanari, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, Giovanni Martinelli, M. Baccarani, M. Cavo
Journal: Blood (2006)
Plasma Brain Natriuretic Peptide Is Associated with Hepatic Veno-Occlusive Disease and Early Mortality After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Keisuke Kataoka, Yasuhito Nannya, Hiroshi Iwata, Sachiko Seo, Keiki Kumano, Tsuyoshi Takahashi, Ryozo Nagai, Mineo Kurokawa
Journal: Blood (2009)
A novel prognostic index to improve patient stratification compared to the Nottingham grading system.
Authors: Hokyung Shin, Sergey Klimov, Guilherme Henrique Cantuaria, Xiaoxian Li, Padmashree C.G. Rida, Remus Osan, Ritu Aneja
Journal: Journal of Clinical Oncology (2015)

e22170 Background: The Nottingham breast tumor Grading System (NGS), renowned for its reproducibility and ease of use, stratifies breast cancer patients into prognostic subgroups and guides therapeutic decisions. Herein we evaluate a breast tumor grading system that uses additional histological parameters along with the traditional NGS components, to create a novel prognostic index. Methods: In a dataset of 1611 breast carcinoma patients, all variables under consideration were transformed into categorical variables using cross-tabulation analysis that finds the death to live ratio. Next, using the newly defined categorical variables, a regression model was developed that only contained the statistical significant variables ; only mitotic index, tubularity, Ki67 Index, Her2 status and Ki67-Adjusted Mitotic Score (which reflects the ratio of mitotic cells to proliferative cells) were included in our model. Using coefficients defined in the model, patients were scored and then stratified into three risk groups using Kolmogorov–Smirnov test (KS test). We performed log rank tests for survival curves, evaluated Cox hazards and concordance indices, alongside the Akaike information criterion (AIC) for model fit. Results: Our model created three risk groups: GI (low risk, n = 1017, 96.24% overall survival or OS), GII (medium risk, n = 156, 90.73% OS) and GIII (high risk, n = 438, 75.23% OS). Hazard ratios (relative to low risk) obtained were 2.4 and 3.61 for GII and GIII, respectively, which presented an improvement compared to 1.97 and 3.37 for Nottingham grade (NG) II and III, respectively. Compared to NGS, our model yielded a superior concordance index (0.73 vs 0.67), lower model fit statistics (AIC = 2103 vs 2125) and a much smaller medium risk group (NGII n = 633). Conclusions: Our rationally designed and simple regression-based model (a) assigns appropriate weights to component parameters and incorporates their variable contributions, (b) presents significant improvement in all discrimination statistics over the NGS. Most importantly, the size of the medium risk group, commonly called the “mixed bag”is dramatically reduced, thus clarifying treatment decisions for a much larger group of patients.
Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials
Authors: Bruno Paiva, María-Belén Vidriales, María-Angeles Montalbán, María-Victoria Mateos, Laura Rosiñol, Joaquin Martinez, María Teresa Cibeira, Lourdes Courdón, Albert Oriol, María José Terol, Maria-Asuncion Echebeste, Raquel de Paz, Felipe de Arriba, Luis Palomera, Javier De La Rubia, Joaquín Díaz-Mediavilla, Jose Garcia-Laraña, Anna Sureda, Ana Gorosquieta, Adrian Alegre, Alejandro Martín, Miguel T. Hernandez, Yolanda Gonzalez, Joan Blade, Juan José Lahuerta, Jesús F. San Miguel
Journal: Blood (2010)
Adaptive memory systems for remembering the salient and the seemingly mundane
Authors: Maureen Ritchey, Vishnu P. Murty, Joseph E. Dunsmoor
Journal: Behavioral and Brain Sciences (2016)

Abstract In an adaptive memory system, events should be prioritized in memory based on their own significance, as well as the significance of preceding or following events. Here we argue that tag-and-capture models complement the GANE (glutamate amplifies noradrenergic effects) model by describing a mechanism that supports the transfer of memory benefits from one event to the next.
FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.
Authors: Kerry J. Savage, Joseph M. Connors, Don Wilson, Richard Klasa, Tamara Shenkier, Paul Hoskins, Nicholas Voss, Laurie H. Sehn
Journal: Blood (2007)
Deletion 13q in B-CLL: Interphase FISH Reveals More 13q- Than Does CpG Stimulation.
Authors: Daniel L. Van Dyke, G.W. Dewald, T.G. Call, D.F. Jelinek, C.S. Zent, T.D. Shanafelt, S.A. Smoley, K.J. Stockero, N.E. Kay
Journal: Blood (2007)
Detection of CALM-AF10 Fusion Transcript Does Not Predict A Poor Prognosis in Children with T-Lineage Acute Lymphoblastic Leukemia Treated with AIEOP ALL 2000 Protocol and Subsequent Modified 2000 Study (R-2006).
Authors: Luca Lo Nigro, Elena Mirabile, Manuela Tumino, Cinzia Caserta, Giovanni Cazzaniga, Carmelo Rizzari, Daniela Silvestri, Elena Barisone, Fiorina Casale, Matteo Luciani, Franco Locatelli, Chiara Messina, Concetta Micalizzi, Andrea Pession, Rosanna Parasole, Nicola Santoro, Giuseppe Masera, Giuseppe Basso, Maurizio Aricò, Maria Grazia Valsecchi, Andrea Biondi, Valentino Conter
Journal: Blood (2009)
Tribbles Homolog 2 (Trib2) Inactivates C/EBPalpha and Causes Acute Myelogenous Leukemia.
Authors: Karen Keeshan, Yiping He, Bas J. Wouters, Olga Shestova, Lanwei Xu, Hong Sai, Carlos G. Rodriguez, Ivan Maillard, Peter Valk, Martin Carroll, Jon C. Aster, Rudd Delwel, Warren S. Pear
Journal: Blood (2006)
Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
Authors: Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner
Journal: Blood (2008)
Does First-Trimester Screening Modify the Natural History of Congenital Heart Disease?
Authors: Hana Jicinska, Pavel Vlasin, Michal Jicinsky, Ilga Grochova, Viktor Tomek, Julia Volaufova, Jan Skovranek, Jan Marek
Journal: Circulation (2017)

The study analyzed the impact of first-trimester screening on the spectrum of congenital heart defects (CHDs) later in pregnancy and on the outcome of fetuses and children born alive with a CHD.The spectrum of CHDs, associated comorbidities, and outcome of fetuses, either diagnosed with a CHD in the first trimester (Group I, 127 fetuses) or only in the second-trimester screening (Group II, 344 fetuses), were analyzed retrospectively between 2007 and 2013. Second-trimester fetuses diagnosed with a CHD between 2007 and 2013 were also compared with Group III (532 fetuses diagnosed with a CHD in the second trimester from 1996 to 2001, the period before first-trimester screening was introduced).The spectrum of CHDs diagnosed in the first and second trimesters in the same time period differed significantly, with a greater number of comorbidities (P<0.0001), CHDs with univentricular outcome (P<0.0001), intrauterine deaths (P=0.01), and terminations of pregnancy (P<0.0001) in Group I compared with Group II. In Group III, significantly more cases of CHDs with univentricular outcome (P<0.0001), intrauterine demise (P=0.036), and early termination (P<0.0001) were identified compared with fetuses diagnosed with CHDs in the second trimester between 2007 and 2013. The spectrum of CHDs seen in the second-trimester groups differed after first-trimester screening was implemented.First-trimester screening had a significant impact on the spectrum of CHDs and the outcomes of pregnancies with CHDs diagnosed in the second trimester. Early detection of severe forms of CHDs and significant comorbidities resulted in an increased pregnancy termination rate in the first trimester.
Improved Prognosis of Children and Adolescents with Acute Lymphoblastic Leukemia (ALL) and Very-High Minimal Residual Disease (MRD) and the End of Induction therapy (EOI)? Preliminary Results of the FRALLE 2000 Protocol
Authors: Jean-Michel Cayuela, Kheira Beldjord, Sylvie Fasola, Marie-Françoise Auclerc, Benoît Brethon, Anne Auvrignon, Francoise Mechinaud, Virginie Gandemer, Geneviève Margueritte, Pascale Blouin, Nathalie Grardel, Hélène Cavé, Elizabeth Macintyre, Leverger Leverger, Andre Baruchel
Journal: Blood (2008)
Resource utilization by palliative surgery patients: results of the decision and outcomes in palliative surgery (DOPS) trial
Authors: Y. D. Podnos, G. Juarez, C. Pameijer, G. Uman, B. R. Ferrell, L. D. Wagman
Journal: Journal of Clinical Oncology (2006)

18543 Background: The number of cancer patients is increasing. Though many cancer treatments are successful at improving survival, most tumors recur and become incurable. A spectrum of symptoms then manifest, many requiring operations. As this happens and the focus becomes symptom management, health system resources used often differ from other scenarios. This study seeks to define the type and breadth of perioperative resource utilization after palliative operations. Methods: Prospectively, patients with advanced malignancies getting palliative operations were followed 3 months postoperatively. In addition to demographics, all encounters with any medical personnel and healthcare resources used were captured by a thorough chart audit and entered into a database. Results: Of the 106 patients entering the study, 67 remained after 3 months. Patients suffered from a mean of 2 symptoms, pain being most common. Patients had a mean of 25.4 encounters (range 1–94). Most commonly, the encounters were with the departments of surgery, medical oncology, and radiation oncology. Half of the encounters were with physicians while 47% were with physician extenders and 3% with supportive staff. Eighty-seven percent of encounters were scheduled. Half occurred in the clinics, 21% in urgent care, and 29% by phone. Fifteen patients were readmitted, most often for symptom management (52%). The 54 patients receiving supportive care referrals had a mean of 2 different referrals per patient and were primarily social work, nutrition, and rehabilitation. Two pain management referrals were initiated. Conclusions: Patients undergoing palliative operations use no more resources than those having curative procedures. Because of disease persistence, the types of resources used differ. Defining these differences is important as health systems plan for the increase in aged with incurable cancers. Early referral to supportive care specialists, vital as symptoms worsen, remains underutilized. Without inclusion of these professions, patient quality of life and distress are not being helped as much as possible. Medical and surgical oncologists should aggressively assess and manage symptoms and consult colleagues to comprehensive symptom management. No significant financial relationships to disclose.
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.
Authors: Hiroshi Yasui, Teru Hideshima, Paola Neri, Janice Jin, Tanyel Kiziltepe, Norihiko Shiraishi, Kenji Ishitsuka, Catley P. Laurence, Noopur Raje, Klaus Podar, Pierfrancesco Tassone, Dharminder Chauhan, Paul G. Richardson, Lorenzo M. Leoni, Sarath Kanekal, Gary T. Elliott, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2005)
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study
Authors: Aristoteles Giagounidis, Ghulam J. Mufti, Hagop M. Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Andrea Kuendgen, Uwe Platzbecker, Gianluca Gaidano, Wieslaw Jedrzejczak, Kuolung Hu, Allen S. Yang, Susie Jun
Journal: Blood (2011)
CBIO-14TARGETING PROTEASOME ACTIVITY WITH MARIZOMIB AS A THERAPEUTIC PERSPECTIVE FOR GLIOMA PATIENTS
Authors: Shahrzad Jalali, Francis Burrows, Mohit Trikha, Gelare Zadeh, Kenneth Aldape
Journal: Neuro-Oncology (2015)

Inhibition of the Ubiquitin-Proteasome pathway offers promise for the treatment of gliomas, but has yet to be tested because the approved drugs in this class don't penetrate the CNS. Marizomib is a novel second-generation proteasome inhibitor, with advantages over bortezomib and carfilzomib including irreversible inhibition of all three enzymatic activities of the proteasome and superior tolerability. While there are some promising data in preclinical models of solid tumors using proteasome inhibitors, only Marizomib has proven active in intracranial GBM xenografts, prompting the initiation of a Phase I trial in GBM in combination with bevacizumab. We aim to identify potential biomarkers predictive of response to Marizomib in GBM patients. Tumor tissues obtained from glioma patients at Toronto Western Hospital and utilized for proteasome activity assay. Glioma Stem Cells (GSC) isolated from freshly resected gliomas and used for in-vitro characterization of Marizomib treatment on GSCs. DNA and RNA were isolated from tumors of the patients (including those participating in the Phase I trial) for mutational analysis and expression of a cancer gene panel. Data shows significant increase in all three proteasome activities, Chymotrypsin-Like, Trypsin-Like and Caspase-Like, in GBM tumors compared to normal brain tissues, suggesting a role for the proteasome in GBM formation. Furthermore, progression of low-grade astrocytoma to GBM is associated with enhanced Chymotrypsin-Like and Trypsin-Like activities, indicating that targeting these subunits could potentially inhibit the progression of gliomas. In vitro analysis using GSC lines indicates that the GSC cells of proneural and mesenchymal origin differ in response to Marizomib, raising the possibility that molecular signatures associated with GBM subtypes could determine the therapeutic response to Marizomib in GBM patients. In conclusion, Marizomib represents as a potential therapeutic agent for GBM. Further investigation is necessary to assess the therapeutic benefits of Marizomib as a single agent or combined with other agents.
Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial
Authors: Carolina Terragna, Angela Flores Dico, Marina Martello, Vincenzo Callea, Gioacchino Catania, Tonino Spadano, Tommaso Caravita di Toritto, Nicoletta Testoni, Anders Waage, Enrica Borsi, Antonio Palumbo, Sonja Zweegman, Annamaria Cafro, Angelo D. Palmas, Silvestro Volpe, Marcella Prete, Ernesto Vigna, Luca De Rosa, Claudia Cellini, Pieter Sonneveld, Michele Cavo
Journal: Blood (2014)
Low Dose Alemtuzumab (Campath 1H) Prior to Allogeneic Stem Cell Transplantation Is Associated with Low Incidence of Acute and Chronic GVHD but Protracted Immune Recovery.
Authors: Marcel P. Devetten, Fausto Loberiza, Robin Weisenborn, Pam Bunner, Jamie Brewer, Solveig Ericson
Journal: Blood (2005)
Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.
Authors: Sook Wah Yee, Joel Mefford, John Witte, Michiaki Kubo, Koichi Matsuda, Kathleen Giacomini, Charalambos Andreadis
Journal: Blood (2012)
The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer
Authors: Tomonari Asano, Suguru Yamada, Tsutomu Fujii, Norimitsu Yabusaki, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Journal: International Journal of Surgery (2017)
Upregulation of MT1-MMP Expression by Hyaluronic Acid Enhances Homing-Related Responses of Hematopoietic CD34+ Cells to an SDF-1 Gradient.
Authors: Neeta Shirvaikar, Jencet Montano, Andrew R. Turner, Mariusz Z. Ratajczak, Anna Janowska-Wieczorek
Journal: Blood (2004)